

# NORIDZA RIVERA - RODRÍGUEZ

E-MAIL • noridza.rivera@upr.edu

## EDUCATION

---

- 2002- 2006      **University of Puerto Rico, School of Medicine, San Juan, P.R.**  
MD, June, 2006  
*Magna cum Laude*
- 1998-2002      **University of Puerto Rico, Rio Piedras Campus, San Juan, P.R.**  
B.S. General Sciences  
*Magna cum Laude*

## POSTDOCTORAL TRAINING

---

- 2016 – 2017      **LEADS fellow in Translational Research: Leading Emerging and Diverse Scientist to Success**  
University of Pittsburgh Institute of Clinical Research Education And UPR Medical Sciences Campus
- 2009 – 2012      **University of Puerto Rico, School of Medicine, University District Hospital San Juan, P.R.**  
Hematology Oncology Fellowship Program
- 2006 – 2009      **University of Puerto Rico, School of Medicine, University District Hospital San Juan, P.R.**  
Internal Medicine Residency Training Program

## PROFESSIONAL EXPERIENCE

---

- 2019- Present.      **Centro Comprensivo de Cáncer de la Universidad de Puerto Rico**  
*Member of the Board of Directors as part of the scientific community expert in cancer*
- 2019 - Present      **Hospital Oncológico de la Liga Puertorriqueña Contra el Cáncer, Dr. Isaac Gonzalez Martínez**  
*Hematologist-Medical Oncologist*  
Hospital based practice providing care for patients with solid tumors and hematologic malignancies
- 2018 - Present      **PanOncology Trials**  
Medical Oncologist and Clinical Investigator  
PanOncology aims to advance the science of oncology by providing access to early phase clinical trials for cancer patients living in Puerto Rico
- 2012 - 2018      **Centro de Cancer Auxilio Mutuo, Auxilio Mutuo Hospital San Juan, PR**  
*Hematologist-Medical Oncologist*  
Comprehensive hospital-based practice providing care and clinical research  
for a variety of hematologic malignancies and solid tumors
- 2016 – 2017      **Private Practice Hematology-Medical Oncology**  
HIMA Plaza Suite 702  
Caguas, PR

# NORIDZA RIVERA - RODRÍGUEZ

E-MAIL • noridza.rivera@upr.edu

## ACADEMIC APPOINTMENTS

---

2012 - Present	<b>Assistant Professor</b> , University of Puerto Rico School of Medicine, Internal Medicine Department Hematology-Medical Oncology Section, San Juan, PR
2017-Present	<b>Interim Director</b> Hematology Oncology Section, UPR School of Medicine, Internal Medicine Department

## HONORS AND AWARDS

---

2014	Roswell Park Cancer Institute: Methods in Clinical Research Workshop for Minority Physician
2011	Research award by Asociación Hematología Oncología Médica de Puerto Rico
2009	Honoric Award Research Symposium University Of Puerto Rico School of Medicine Internal Medicine Program
2005	Elected Member Alpha Omega Alpha (ΑΩΑ) Medical Honor Society (Elected in Junior Year)
2004	American Society for Clinical Pathology Award for Academic Excellence and Achievement
2003	School of Medicine Honor Roll
2002	University of Puerto Rico Dean's List
2001	Department of Natural Sciences Honor Roll

## BOARDS AND CERTIFICATIONS

---

<b>USMLE STEP 1</b>	Approved (July 2004)
<b>USMLE STEP 2 CK</b>	Approved (September 2005)
<b>USMLE STEP 2 CS</b>	Approved (June 2006)
<b>USMLE STEP 3</b>	Approved (September 2008)
<b>American Board of Internal Medicine</b>	Approved (August 2009)
<b>American Board of Internal Medicine Medical Oncology</b>	Approved (October 2012)
<b>American Board of Internal Medicine Hematology Practice of</b>	Approved (November 2013)
<b>NIH Introduction to the Principles and Practice of</b>	Approved (October 2014-March 2015)
<b>Clinical Research NIDA Clinical Trials Network: Good Clinical Practices Program Human Research/Biomedical Research</b>	Approved (May 2016)
<b>CITI</b>	Completed (September 2019)

Basic Course

MEDICAL LICENSE

---

# NORIDZA RIVERA - RODRÍGUEZ

E-MAIL • noridza.rivera@upr.edu

Puerto Rico 17,486

## Hospital Affiliations

Hospital Universitario Adultos, San Juan PR	2012-Present	<b>PUBLICATIONS AND RESEARCH PRESENTATIONS</b>
<b>Member of Pharmacy Committee</b>	<b>2015-Present</b>	
<b>Director of the Leukemia Unit and Chemotherapy Ambulatory Unit</b>	<b>2017-Present</b>	Rivera Lynch, Camila, Centeno-Girona,
Hospital Auxilio Mutuo San Juan, PR	2012-Present	Hilmaris, Soto-Salgado, Marivelisse, Rivera, Noridza, MD; Poorman,
Hospital Oncológico Dr. Isaac González San Juan, PR	2014-Present	Kelsey, CruzCorrea, Marcia. Interrogating the molecular profile of solid tumors in Puerto
<b>President of Health Information Management Committee</b>	<b>2019-Present</b>	

Rican Hispanics: Defining actionable mutations and drivers of carcinogenesis. AACR Virtual Science Of Cancer Health Disparities Conference (Oral Presentation). October 2020

Cabanillas F, Rivera N, Acosta M, Pardo W, Solivan P, Rivera C, Liboy I A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev). Clin Lymphoma Myeloma Leuk. 2019 Jul 17

Ortega JL, Cabanillas F, Rivera N, Tirado-Gomez M, Hallman D, Pardo WI, Bruno M. Results of upfront therapy in Marginal Zone Lymphomas. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):879-883

Cabanillas F, Rivera N. Check this checkpoint inhibitor in lymphoma. Blood. 2017 Jul 20;130(3):234-235

Cabanillas F, Liboy I, Cruz A, Solivan PG, Rivera N, Pardo WI, Acosta M. Results of GROC-rev salvage regimen: Gemcitabine, rituximab, and oxaliplatin chemotherapy with revlimid for relapsed/refractory aggressive non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology 35, no. 15\_suppl (May 2017) 7556-7556

Cabanillas F, Rivera N, Pardo WI. Indole lymphomas that present with clinically aggressive features: A subset of low grade lymphomas with the behavior inconsistent with the histologic diagnosis. Clin Lymph Myeloma\_Leuk 2016 Oct16:550-557

Rivera-Rodriguez N, Cabanillas F. Recent Advances in the management of mantle cell lymphoma. Current opinions in oncology. 2013; 26: 717-721

Lopez-Lopez L, Rivera Rodriguez N, Vila LM. Nitrofurantoin-induced microangiopathic haemolytic anaemia and thrombocytopaenia in a patient with systemic lupus erythematosus. BMJ Case Rep. 2012 Sep 12;2012

Marti AA, Rivera N, Soto K, Maldonado L, Colon JL. Intercalation of Re(phen)(CO)3Cl into zirconium phosphate: a water insoluble inorganic complex immobilized in a highly polar rigid matrix. Dalton Transactions 2007, May 7;(17) 1713-8

Noridza Rivera-Rodriguez, Fernando Cabanillas, Lesley Lawrenson, Viviana Negron, Orestes Antonio Pavia, Margarita Bruno, Miguel M. Echenique, Victor Carlo, Idalia Liboy. Results of a novel neoadjuvant chemotherapy (NAC) regimen for breast cancer. San Antonio Breast Cancer Symposium. Poster P3-14-17. December 12, 2013

Jose Luis Ortega, Maribel Tirado-Gomez, Fernando Cabanillas, Noridza Rivera-Rodriguez, Carlos Torres, Karen Ortiz. Epidemiologic findings of non-Hodgkin lymphoma (NHL) in Puerto Rico (PR). J Clin Oncol 31, 2013 (suppl; abstr e19505)

Fernando Cabanillas, Jose Luis Ortega, Noridza Rivera-Rodriguez, Blanca Rodriguez, Wandaly Ibis Pardo, Orestes Antonio Pavia, Margarita Bruno, Karen J. Santiago. Results of upfront therapy for marginal zone lymphoma (MZL). J Clin Oncol 31, 2013 (suppl; abstr e19510)

Noridza Rivera-Rodriguez, Fernando Cabanillas, Carlos Montalban, Jose Francisco Tomas, María José Terol, Armando López-Guillermo, Wandaly I. Pardo, Orestes A. Pavia, Margarita Bruno, Karen Janice Santiago, Pablo Guisado-Vasco,

# NORIDZA RIVERA - RODRÍGUEZ

E-MAIL • noridza.rivera@upr.edu

Angel Ruedas, Raquel de Oña, Silvia Solorzano, Ana Isabel Teruel, Laura Garcia-Sanchis, Jordina Rovira, and Ivan Dlouhy. The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL) Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 1596 (Poster Presentation)

Rivera-Rodriguez N, Cabanillas F, Pardo W, Santiago K, Pavia O, Bruno M. Absolute lymphocyte count (ALC), absolute monocyte count (AMC), and ALC/AMC ratio to predict outcome in aggressive non-Hodgkin lymphoma (aNHL). J Clin Oncol 30, 2012 (suppl; abstr e18547)

Tirado-Gomez M, Munoz C, Cordero P, Fonseca S, Bernabe R, Lacourt M, Rivera N, Cotto M. DNA Methylation Status of MLH1, p16, ER, CDH1 and SOCS1 in Puerto Rican Patients with Acute Myeloid Leukemia. Poster Presentaion at NCI Translational Science Meeting. Washington DC. July 2011

## PUBLICATIONS AND RESEARCH PRESENTATIONS (CONT)

---

Rivera Noridza, Cotto Maribel, Lopez Alberto, Tirado Maribel, Pacheco Eileen. T-Cell prolymphocytic leukemia: A case presentation of a rare leukemia. Poster presentation at the “XXXI Foro Anual de Investigacion y educacion, Recinto de Ciencias Medicas” San Juan Puerto Rico. May 2011

Rivera Noridza, Castro Justiniano Fradera Jean, Pacheco Eileen. The Relationship between Karyotype, Immunophenotype, and Clinical Features in Patients with CD56 Positive Acute Myelogenous Leukemia. Oral Presentation at Research Symposium University of Puerto Rico School of Medicine, Internal Medicine Training Program San Juan Puerto Rico, May 2009

Rivera, Noridza; Martinez, Angel; Colon, Jorge, Prof., UPR-Rio Piedras, Natural Sciences, Department of Chemistry: Ion-Exchange of Re(bpy)(CO)<sub>3</sub>Cl into alpha-Zirconium Phosphate Layer. Oral Presentation at 37<sup>th</sup> ACS Junior Technical Meeting University of Puerto Rico, Arecibo Campus, Arecibo, May 2002

## RESEARCH EXPERIENCE (Active) September 2020-Present

---

Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors  
*Sub-PI*

### September 2020-Present

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)  
*Principal Investigator*

### August 2020-present

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer. NCT04264702, SIGNATERA,  
*Sub-PI*

### July 2020-Present

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants with Advanced Non-Small Cell Lung Cancer. NCT04077463, Janssen Research Development. *Sub PI*

### July 2020-Present

A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with

# NORIDZA RIVERA - RODRÍGUEZ

E-MAIL • noridza.rivera@upr.edu

Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivolumab clinical Trial Evaluation 7DX). NCT04100018, *Sub-PI*

## July 2020-Present

A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-arterial ChemoEmbolization (TACE) in Patients with Intermediate-stage Hepatocellular Carcinoma (HCC). NCT04340193

*Sub-PI*

## June 2020-Present

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine with Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Trial. NCT03773302, QED Therapeutics.

*Sub-PI*

A Phase 1b Study of Venetoclax and Capecitabine In Subjects with Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Progression During or After CDK4/6 Inhibitor Therapy. NCT04274933, AbbVie.

*Principal Investigator*

## January 2020-Present

Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M). NCT04102020, AbbVie.

*Principal Investigator*

## January 2020-Present

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992). NCT04241185, Merck Sharp & Dohme. *Sub-PI*

## November 2019-Present

A phase 2 study of olaparib in combination with pembrolizumab in participants with previously treated Homologous Recombination Repair Mutation and/or Homologous Recombination Repair Deficiency positive advance cancer *Sub-PI*

## October 2019-Present

A multicenter Phase 1, Open -label dose escalation study of the safety, tolerability, and pharmacokinetics of ABBV-368 as a single agent and combination in subjects with locally advance or metastatic solid tumors *Principal Investigator*

## September 2019-Present

A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis Janssen CNTO1959COR1001

*Sub-PI*

## M15-999: (August 2019)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Risankizumab Using a New Formulation for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis *Sub-PI*

## July 2019-Present

A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer, BMS CA-209-8HW

*Sub-PI*

# NORIDZA RIVERA - RODRÍGUEZ

E-MAIL • noridza.rivera@upr.edu

## January 2019-Present

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) plus Platinum and Fluoropyrimidine Versus Placebo plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

*Sub-PI*

## December 2018-Present

A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD) BGB290-202 *Sub-PI*

## LECTURES AND CONFERENCES (Invited as Speaker)

---

9<sup>th</sup> Annual PR Winter Cancer Symposium: Moderator and Speaker: Her2 Breast Cancer Management. March 2020, San Juan PR

Centro de Cancer Auxilio Mutuo Post ASH 2019 Meeting Highlights: Myeloproliferative Disorders. Feb 2020, San Juan PR

Immunotherapy in Lung Cancer: An Evolving Strategy. Lung Cancer Symposium: Discoveries in Lung Cancer. San Juan, PR November 2019

Puerto Rico Immuno-Oncology Academy Conference Series: Emerging Considerations in the Use of Immune Checkpoint Inhibitors: CRC. San Juan PR, November 2019

Precision Medicine Strategies in Liver and Pancreatic Cancers. Gastrointestinal Cancer Symposium: Innovations in Endoscopic, Surgical, and Oncologic approaches. San Juan PR. August 2019

Breast Cancer Local Regional and Adjuvant Meeting Highlights. Centro de Cáncer Auxilio Mutuo Post ASCO Oncology Review 2019. San Juan PR. June 2019

Immunooncology Therapy: What? Who? When? Personalized Medicine for the Prevention and Treatment of Colorectal Cancer. Mayaguez, PR June 2019

Oncology Update: Immunotherapy Case Discussion. UPR School of Medicine Urology Department: Regreso a Casa. San Juan, PR. May 2019

Triple Negative Breast Cancer: Still Jurassic Park? Speaker and Moderator of Breast Cancer Session. 8th Annual Puerto Rico Fall Cancer Symposium. March 2019

Cancer Colorectal: Deteccion Temprana: Taller Ministerio Renace. San Juan, PR. March 2019

Centro de Cancer Auxilio Mutuo Post ASH 2019 Meeting Highlights: Myeloproliferative Disorders. San Juan, PR. February 2019

UPR School of Medicine Internal Medicine Grand Round: Immunotherapy for Cancer Treatment: Beyond the Novel Prize. October 2018

Preconvention Pulmonary and Sleep Medicine: Immunotherapy and Targeted Therapy in Lung Cancer. September 2018

1<sup>st</sup> Congress of Colorectal Cancer Management: Expanding Treatment Options in Colorectal Cancer: What Role Do Cancer Immunotherapies Have? August 2018

# NORIDZA RIVERA - RODRÍGUEZ

E-MAIL • noridza.rivera@upr.edu

Centro de Cancer Auxilo Mutuo ASCO Review 2018: Multiple Myeloma Meeting Highlights. June 2019, San Juan PR  
Immunotherapy in Cancer: The Next Frontier is Here: Multiple Locations, in Puerto Rico March and April 2018

PR Winter Symposium Management of Metastatic Breast Cancer, March 2018

Centro de Cancer Auxilo Mutuo ASCO Review 2017: Breast Cancer and Multiple Myeloma Meeting Highlights. June 2017, San Juan PR

Centro Comprensivo de Cancer de la UPR, PR Breast Cancer Chemotherapy Management, February 2017, San Juan PR  
PR Fall Cancer Symposium Adjuvant and Neoadjuvant Therapy in non HER2 Breast Cancer October 2016

UPR School of Medicine Plasma Cell Dyscrasia, April 2016

UPR School of Medicine. Targeted Therapies in Oncology. April 2013, and March 2014.

## LECTURES AND CONFERENCES (Invited as Speaker, CONT)

---

Centro de Cancer Auxilo Mutuo ASCO Review 2013: Breast Cancer Meeting Highlights. June 2013, San Juan PR

Centro de Cancer Auxilo Mutuo Post ASH 2012 Meeting Highlights: Multiple Myeloma. February 2013, San Juan PR

Centro de Cancer Auxilo Mutuo ASCO Review 2012: Breast Cancer Meeting Highlights. August 2012, San Juan PR

Centro de Cancer Auxilo Mutuo ASCO Review 2011: Breast Cancer Meeting Highlights. August 2011, San Juan PR

Centro de Cancer Auxilo Mutuo Post ASH 2009 Meeting Highlights: Multiple Myeloma. February 2012, San Juan PR

## PROFESSIONAL ASSOCIATIONS AND COLABORATIONS

---

Member of the American Hematology Society

Member of the American Society of Clinical Oncology

Member of the Asociación de Hematología y Oncología Médica de Puerto Rico (**Secretary** 2013-2018, **President of the Scientific Committee** 2018-2019). **Treasurer** (2019-Present)

Associate of the Asociación Internacional de Hematología

Alpha Omega Alpha, UPR School of Medicine, Board of Directors 2005-2006

Member of Colegio de Médicos Cirujanos de Puerto Rico

Susan G Komen of Puerto Rico, Panel for Proposal Revision 2013 and 2017

Bristol Myers Squibb Speaker Bureau 2016-Present

Merck Speaker Bureau 2017-Present

Abbvie Speaker Bureau 2019-Present

Esai Speaker Bureau 2020-Present

## REFERENCES

---

Available upon request